Trenonacog alfa

Product Description

IB1001, N-acetyl-L-leucine, is an orally administered modified amino acid. In vivo studies have identified N-acetyl-L-leucine to be the active isomer of N-acetyl-DL-leucine that can restore neuronal function and protect against/delay disease progression in multiple neurological circuits of the brain. The mechanism of N-acetyl-L-leucine is multi-modal, including altered glucose and antioxidant metabolism, reduced lysosomal storage, and the reduction of neuroinflammation in the cerebellum, leading to the attenuation of cell death. (Sourced from: https://intrabio.com/2021/08/19/intrabio-reports-statistically-significant-and-clinically-meaningful-improvements-in-the-use-of-ib1001-for-treatment-of-gm2-gangliosidosis/)

Mechanisms of Action: FIX Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IntraBio
Company Location:
Company CEO:
Additonal Commercial Interests: None